- Home
- DRCT vs NCNA Comparison
DRCT vs NCNA Comparison
Compare DRCT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- NCNA
- Stock Information
- Founded
- DRCT 2018
- NCNA 1997
- Country
- DRCT United States
- NCNA United Kingdom
- Employees
- DRCT N/A
- NCNA N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- NCNA Health Care
- Exchange
- DRCT Nasdaq
- NCNA Nasdaq
- Market Cap
- DRCT 8.8M
- NCNA 7.6M
- IPO Year
- DRCT 2022
- NCNA 2017
- Fundamental
- Price
- DRCT $0.35
- NCNA $4.20
- Analyst Decision
- DRCT Strong Buy
- NCNA
- Analyst Count
- DRCT 1
- NCNA 0
- Target Price
- DRCT $6.00
- NCNA N/A
- AVG Volume (30 Days)
- DRCT 5.5M
- NCNA 536.4K
- Earning Date
- DRCT 11-07-2025
- NCNA 11-24-2025
- Dividend Yield
- DRCT N/A
- NCNA N/A
- EPS Growth
- DRCT N/A
- NCNA N/A
- EPS
- DRCT N/A
- NCNA N/A
- Revenue
- DRCT $36,459,000.00
- NCNA N/A
- Revenue This Year
- DRCT $16.81
- NCNA N/A
- Revenue Next Year
- DRCT $35.28
- NCNA N/A
- P/E Ratio
- DRCT N/A
- NCNA N/A
- Revenue Growth
- DRCT N/A
- NCNA N/A
- 52 Week Low
- DRCT $0.28
- NCNA $2.78
- 52 Week High
- DRCT $6.59
- NCNA $366.00
- Technical
- Relative Strength Index (RSI)
- DRCT 48.96
- NCNA 45.06
- Support Level
- DRCT $0.33
- NCNA $3.81
- Resistance Level
- DRCT $0.37
- NCNA $4.40
- Average True Range (ATR)
- DRCT 0.05
- NCNA 0.52
- MACD
- DRCT 0.00
- NCNA -0.20
- Stochastic Oscillator
- DRCT 26.61
- NCNA 15.22
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.